Cholangiocarcinoma (Bile Duct Cancer) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Cholangiocarcinoma (Bile Duct Cancer) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
(EMAILWIRE.COM, November 30, 2017 ) Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market:
By Therapy Type (Drug Therapy (Gemcitabine Combination Therapy, 5-fluorouracil Combination Therapy, Capecitabine Combination Therapy, and Gemcitabine Alone) Radiation Therapy (Brachytherapy and External Beam Radiation Therapy (EBRT), and Surgery), By Disease Indication (Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer and Distal Extrahepatic Bile Duct Cancer)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Report Description:
Global bile duct cancer treatment market report gives comprehensive outlook on cholangiocarcinoma (bile duct cancer) therapies across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on cholangiocarcinoma (bile duct cancer) treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of a therapy type, disease indication, and geographic regions. This report studies cholangiocarcinoma (bile duct cancer) treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, cholangiocarcinoma (bile duct cancer) treatment market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed cholangiocarcinoma (bile duct cancer) treatment market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Therapy Opportunities). Key stakeholders of the cholangiocarcinoma (bile duct cancer) treatment market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of cholangiocarcinoma (bile duct cancer) therapies.
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-njYIhocMn4o6wrda
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market:
Global cholangiocarcinoma (bile duct cancer) treatment market estimated to be valued US$ 184 Mn in 2017 and poised to grow at CAGR of 8.1% over 2017-2023. Market for cholangiocarcinoma (bile duct cancer) treatment projected to reach US$ 293 Mn by 2023 owing to growing prevalence of bile duct cancer and incidence of liver fluke infections in developing countries
Growing prevalence of liver and bile duct cancer in developed and developing markets driving market revenue growth
The market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe. Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.
Rising industrialization and orphan drug designation for bile duct cancer therapies likely impact market growth positively
The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.
To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-c654SbFYO64MsOhu
Asia-Pacific emerged as prominent region for cholangiocarcinoma (bile duct cancer) treatment market across the globe
The Asia-Pacific market is expected to hold the larger revenue share in global cholangiocarcinoma (bile duct cancer) treatment market and projected to remain dominant over the forecast period owing to growing prevalence and incidence of bile duct cancer in the region. North America cholangiocarcinoma (bile duct cancer) treatment market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to orphan designation status for drug molecules in the recent times for treating cholangiocarcinoma
Competition Assessment
Key players profiled in the global Cholangiocarcinoma (Bile Duct Cancer) Treatment market include:
• Accord Healthcare Inc. (UK)
• Bristol-Myers Squibb Company (U.S)
• Celgene Corporation (U.S)
• Delcath Systems Inc. (U.S)
• Eli Lilly and Company. (U.S)
• F. Hoffman-La Roche AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Johnson & Johnson Services Inc. (U.S)
• Kyowa Hakko Kirin Co Ltd. (Japan)
• Mylan N.V. (U.S)
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S)
• Sanofi (France)
• Teva Pharmaceuticals Industries Ltd. (Israel)
Players in cholangiocarcinoma (bile duct cancer) treatment market are focusing on introducing newer and innovative therapies to garner larger market revenue share in global cholangiocarcinoma (bile duct cancer) treatment market.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-14mlyhjMGhVjZqa3
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
By Therapy Type (Drug Therapy (Gemcitabine Combination Therapy, 5-fluorouracil Combination Therapy, Capecitabine Combination Therapy, and Gemcitabine Alone) Radiation Therapy (Brachytherapy and External Beam Radiation Therapy (EBRT), and Surgery), By Disease Indication (Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer (Perihilar Bile Duct Cancer and Distal Extrahepatic Bile Duct Cancer)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Report Description:
Global bile duct cancer treatment market report gives comprehensive outlook on cholangiocarcinoma (bile duct cancer) therapies across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on cholangiocarcinoma (bile duct cancer) treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of a therapy type, disease indication, and geographic regions. This report studies cholangiocarcinoma (bile duct cancer) treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, cholangiocarcinoma (bile duct cancer) treatment market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed cholangiocarcinoma (bile duct cancer) treatment market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Therapy Opportunities). Key stakeholders of the cholangiocarcinoma (bile duct cancer) treatment market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of cholangiocarcinoma (bile duct cancer) therapies.
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-njYIhocMn4o6wrda
Global Cholangiocarcinoma (Bile Duct Cancer) Treatment Market:
Global cholangiocarcinoma (bile duct cancer) treatment market estimated to be valued US$ 184 Mn in 2017 and poised to grow at CAGR of 8.1% over 2017-2023. Market for cholangiocarcinoma (bile duct cancer) treatment projected to reach US$ 293 Mn by 2023 owing to growing prevalence of bile duct cancer and incidence of liver fluke infections in developing countries
Growing prevalence of liver and bile duct cancer in developed and developing markets driving market revenue growth
The market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe. Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.
Rising industrialization and orphan drug designation for bile duct cancer therapies likely impact market growth positively
The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.
To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-c654SbFYO64MsOhu
Asia-Pacific emerged as prominent region for cholangiocarcinoma (bile duct cancer) treatment market across the globe
The Asia-Pacific market is expected to hold the larger revenue share in global cholangiocarcinoma (bile duct cancer) treatment market and projected to remain dominant over the forecast period owing to growing prevalence and incidence of bile duct cancer in the region. North America cholangiocarcinoma (bile duct cancer) treatment market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to orphan designation status for drug molecules in the recent times for treating cholangiocarcinoma
Competition Assessment
Key players profiled in the global Cholangiocarcinoma (Bile Duct Cancer) Treatment market include:
• Accord Healthcare Inc. (UK)
• Bristol-Myers Squibb Company (U.S)
• Celgene Corporation (U.S)
• Delcath Systems Inc. (U.S)
• Eli Lilly and Company. (U.S)
• F. Hoffman-La Roche AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Johnson & Johnson Services Inc. (U.S)
• Kyowa Hakko Kirin Co Ltd. (Japan)
• Mylan N.V. (U.S)
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S)
• Sanofi (France)
• Teva Pharmaceuticals Industries Ltd. (Israel)
Players in cholangiocarcinoma (bile duct cancer) treatment market are focusing on introducing newer and innovative therapies to garner larger market revenue share in global cholangiocarcinoma (bile duct cancer) treatment market.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/global-cholangiocarcinoma-bile-duct-cancer-treatment-market/#ulp-14mlyhjMGhVjZqa3
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Contact Information:
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results